Skip to main content
TipRanks
Go Ultimate75% OFF

Achieve Life Sciences (SP4P) Stock Price & Analysis

3 Followers

SP4P Stock Chart & Stats

€5.35-€0.15(-2.73%)
At close: 5:30 PM GMT+1
€4€5€6€7Jun 22Jul 6Jul 16Aug 19Sep 4Sep 18
Day’s Range
EUR 5.35 - EUR 5.35
52-Week Range
EUR 2.29 - EUR 7.25
Previous Close
EUR 5.50
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 555.56M
Enterprise Value
EUR 665.84M
Total Cash (Recent Filing)
EUR 201.52M
Total Debt (Recent Filing)
EUR 13.76M
Price to Earnings (P/E)
―
Beta
1.47
Next Earnings
Mar 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Smoking-cessation Pipeline

A focused lead program targeting nicotine dependence gives Achieve Life Sciences a clear strategic direction and addresses a defined public-health need. If development and approval succeed, cytisinicline could support a specialized prescription-product business rather than a diversified but unfocused pipeline.

Regulatory And Launch Preparation

Preparation for NDA resubmission and a planned commercial launch indicate progress toward converting the company from a development-stage operation into a potential prescription-product business. This creates a pathway to future revenue and broader operating leverage, although approval remains necessary.

Manageable Debt And Equity Cushion

Manageable absolute debt and a sizable equity balance provide some financial capacity to continue research and development while the lead product remains investigational. This cushion may reduce immediate balance-sheet pressure, although it does not eliminate the need for funding while losses continue.

Bears Say

Minimal Revenue And Severe Losses

The company has not yet demonstrated a functioning commercial revenue base, while losses are extremely large relative to reported sales. Persistent negative profitability leaves the business dependent on successful clinical and regulatory execution before meaningful operating leverage can emerge.

Persistent Cash Burn

Sustained negative operating and free cash flow means the company consumes capital to fund its operations and development programs rather than generating internal funding. Continued or increasing burn can shorten financial flexibility and raise the need for additional capital before commercialization.

Dependence On External Financing

Because the investigational product has not established commercial sales, ongoing operations rely on financing activities and external capital. This dependence can constrain strategic flexibility and expose shareholders to dilution or unfavorable financing terms if losses persist.

Achieve Life Sciences News

SP4P FAQ

What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was €2.29 and its highest was €7.25 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is €555.56M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s next earnings report is estimated for Mar 11, 2027 (not yet confirmed), which is in 110 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on Nov 10, 2026. The company reported -€0.1 earnings per share for the quarter, beating the consensus estimate of -€0.182 by €0.082.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.18.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 102,902,490 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -€0.1 in its last earnings report, beating expectations of -€0.182. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Hedge funds hold Achieve Life Sciences shares: the largest hedge-fund position in Achieve Life Sciences is 14,284,975 shares, and hedge funds decreased their holdings by 42.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology